Paris, FRANCE
More info
News & events
Innate Pharma reports today its consolidated financial results for the year ending December 31, 2009 and updates on its drug candidates
March 5, 2010
Progress of clinical portfolio and strenghtnening of cash position.
Innate Pharma reports today its consolidated financial results for the year ending December 31, 2009.
Unaudited consolidated financial statements are attached to this press release.
Innate Pharma reports operating revenue of 7.7 million euros for 2009
February 5, 2010
(IFRS unaudited provisional data)
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces an operating revenue of 7.7 million euros for the year 2009. Turnover for the year amounted 3.3 million euros, including 0.5 million euros in the fourth quarter ended December 31, 2009.
Number of shares and voting rights and cash situation of INNATE PHARMA as at December 31, 2009
January 8, 2010
Following the capital increase reserved to categories of investors executed in December 2009 and pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (“AMF”) charter, Innate Pharma SA updates its total number of shares outstanding as well as its voting rights as at December 31, 2009:
Half-year report on INNATE PHARMA’S liquidity contract with NATIXIS SECURITIES
January 8, 2010
Under the liquidity contract entrusted by Innate Pharma to Natixis Securities, the following assets appeared on the liquidity account as at December 31, 2009:
- 69,741 shares of Innate Pharma, and
- 121,955.05 euros in cash.
Innate Pharma announces its financial and investor relations calendar for 2010 and the settlement and delivery of its capital increase
December 23, 2009
- Innate Pharma announces today its tentative financial and investor relations calendar for 2010.
- The Company also announces today the settlement and delivery of its capital increase reserved to categories of investors announced on December 18, 2009. 10,724,535 new shares were issued. The gross proceeds amount to 24.3 million euros (issuance premium included) and the net proceeds amount to 23.1 million euros.
Innate Pharma announces today a capital increase of a maximum of 24.3 million euros reserved to categories of investors
December 18, 2009
- The “Fonds Stratégique d’Investissement” (French sovereign fund) invested 11 million euros
- Novo Nordisk A/S and Alta Partners, two historical shareholders of the Company, also participated in the transaction